Please login to the form below

Not currently logged in
Email:
Password:

Alcon and AstraZeneca in eye collaboration

Alcon has entered into a five-year research agreement with AstraZeneca targeting the development of drugs to treat sight-threatening conditions

Under the terms of the agreement Alcon will gain exclusive access to AstraZeneca's extensive range of drug compounds relevant to ophthalmology. The two companies hope the deal will lead to the development of drugs to treat conditions such as wet and dry age-related macular degeneration, glaucoma and other retinal diseases and eye conditions. The partnership pairs Alcon's ophthalmic research capabilities with AstraZeneca's vast compound library.

Jan Lundberg, AstraZeneca's executive vice president of global discovery research said: "We are constantly looking for new opportunities to maximise our strong early pipeline and this collaboration is proof of its value beyond the therapy areas for which AstraZeneca is renowned."

As part of the agreement, Alcon will fund all research and development activities. Any compound moving into clinical development has the potential to be licensed individually to include potential milestone and royalty payments. Alcon is also free to pursue any compounds it develops itself, or licences from other companies, prior to the initiation of confirmatory phase III clinical trials.

"I believe this partnership will not only benefit both parties, but will also lead to new therapies that reduce the incidence of blindness around the world," said Kevin Buehler, Alcon's president and chief executive officer.

23rd July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics